Wearable Biosensors Can Tell When You Are Getting Sick

January 20, 2017 Scipreneur Private Limited 0

Wearable Biosensors Can Tell When You Are Getting Sick By: JENNIE DUSHECK : Stanford News January 20, 2017 New research from Stanford shows that fitness monitors and other wearable biosensors can tell when an individual’s heart rate, skin temperature and other measures are abnormal, suggesting possible illness. Wearable sensors that monitor heart [..]

FDA approval to Trulance of Synergy Pharmaceuticals: for Chronic Idiopathic Constipation

January 20, 2017 Scipreneur Private Limited 0

FDA approval to Trulance of Synergy Pharmaceuticals : for Chronic Idiopathic Constipation By: News Synergy Pharmaceuticals January 20, 2017 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE™ (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC). TRULANCE is the first drug designed [..]

FDA grants Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional type of advanced bladder cancer

January 17, 2017 Scipreneur Private Limited 0

FDA grants Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional type of advanced bladder cancer TECENTRIQ being evaluated as first-line treatment option for people not eligible for cisplatin chemotherapy Second Priority Review granted for TECENTRIQ in advanced bladder cancer  From Roche News 18 January 2017 Roche (SIX: RO, ROG; [..]

FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization

January 17, 2017 Scipreneur Private Limited 0

FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization Myopic CNV is a complication of severe near-sightedness and most commonly affects people between ages 45 and 64 Granted Priority Review by the FDA Fifth FDA-approved indication for Lucentis since its launch in 2006 By: Genentech News January 18, 2017 [..]

A Step Toward Renewable Diesel

January 17, 2017 Scipreneur Private Limited 0

A Step Toward Renewable Diesel By: Anne Trafton | MIT News Office January 18, 2017 MIT engineers have genetically reprogrammed a strain of yeast so that it converts sugars to fats much more efficiently, an advance that could make possible the renewable production of high-energy fuels such as diesel. The [..]

Some Catalysts Contribute Their Own Oxygen For Reactions

January 10, 2017 Scipreneur Private Limited 0

Some Catalysts Contribute Their Own Oxygen For Reactions By: David L. Chandler | MIT News Office January 10, 2017 Chemical reactions that release oxygen in the presence of a catalyst, known as oxygen-evolution reactions, are a crucial part of chemical energy storage processes, including water splitting, electrochemical carbon dioxide reduction, [..]

Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders

January 9, 2017 Scipreneur Private Limited 0

Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated levels of lipoprotein Lp(a) or ApoCIII, which [..]

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab)

January 9, 2017 Scipreneur Private Limited 0

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab) January 9, 2017  Pfizer Inc. (NYSE:PFE) announced that the comparative, confirmatory REFLECTIONS B538-02 study met its primary objective by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 [..]

New Oral Drug, Selumetinib Demonstrates Shrinkage in Pediatric Neural Tumors in Early-Phase Trial

January 1, 2017 Scipreneur Private Limited 0

New Oral Drug, Selumetinib Demonstrates Shrinkage in Pediatric Neural Tumors in Early-Phase Trial  January 1, 2017 By: NIH News In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, [..]

International Engineering & Technology Fair

December 26, 2016 Scipreneur Private Limited 0

International Engineering & Technology Fair 02-04 Feb 2017  Pragati Maidan, New Delhi, India 22nd IETF 2017 The International Engineering and Technology Fair is now in its 22nd edition. A comprehensive business-to-business event segmented into 11 focused engineering and manufacturing sections, the event is an unparalleled platform for networking and getting discovered [..]

Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca

December 23, 2016 Scipreneur Private Limited 0

Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca December 23, 2016 Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of the development and commercialization rights to AstraZeneca’s late-stage small molecule anti-infective business, primarily outside the United States. The agreement includes the commercialization and development rights [..]

Artificial Leaf as Mini-Factory For Medicine

December 22, 2016 Scipreneur Private Limited 0

Artificial Leaf as Mini-Factory For Medicine Eindhoven University of Technology News December 22 2016 To produce medicine sustainably and cheaply, anywhere you want. Whether in the middle of the jungle or even on Mars. A ‘mini-factory’ whereby sunlight can be captured to make chemical products. Inspired by the art of [..]

Mystery Molecule is a Key to Inhibiting Colon Cancer

December 22, 2016 Scipreneur Private Limited 0

Mystery Molecule is a Key to Inhibiting Colon Cancer St. Jude Children’s Research Hospital News December 22, 2016 Immunologists at St. Jude Children’s Research Hospital have discovered that a protein called NLRC3 plays a central role in inhibiting colon cells from becoming cancerous. The study, led by Thirumala-Devi Kanneganti, Ph.D., [..]